MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

Authors: Ying Meng, Raymond M. Reilly, Rossanna C. Pezo, Maureen Trudeau, Arjun Sahgal, Amit Singnurkar, James Perry, Sten Myrehaug, Christopher B. Pople, Benjamin Davidson, Maheleth Llinas, Chinthaka Hyen, Yuexi Huang, Clement Hamani, Suganth Suppiah, Kullervo Hynynen, Nir Lipsman - Science Translational Medicine 2021 cited by 220

In-BzDTPA-NLS-trastuzumab SPECT imaging. The standardized uptake value ratio (SUVR) of MRgFUS-treated lesions increased, on average, by 101 ± 71%, compared to −18 ± 26% in control lesions. MRgFUS enhanced drug uptake in 87 ± 17% of sonicated voxels (>20% increase in SUVR), with up to a 450% voxel-wise increase detected. Control lesions had 8 ± 8% voxels with >20% increase in SUVR. With treatment, unidimensional tumor measurements decreased by 19 ± 12%. This study provides first-in-human evidence of noninvasive, spatially targeted monoclonal antibody delivery across the BBB using MRgFUS, demonstrating the promise of this technology for a broad range of CNS diseases.